HFpEF and diabetes

Treatment with the SGLT2 inhibitor dapagliflozin improves symptoms and physical function in people with heart failure and preserved ejection fraction, suggest findings from the PRESERVED-HF trial.

Empagliflozin treatment produces significant reductions in the risk for a broad range of inpatient and outpatient heart failure outcomes in people with a preserved ejection fraction, shows further analysis of EMPEROR-Preserved.

Empagliflozin has become the first medication to demonstrate a clear protective effect in people with heart failure and preserved ejection fraction, report the EMPEROR-Preserved investigators.

Mikhail Kosiborod outlines the findings from the PRESERVED-HF trial, demonstrating that dapagliflozin improves symptoms and physical function in people with heart failure with preserved ejection fraction, and discusses the promise of SGLT2 inhibitors for meeting the treatment goals in this population. 

Kevin Fernando discusses the EMPEROR-Preserved findings and their likely impact on the treatment of people with heart failure with preserved ejection fraction, with or without diabetes, in primary care.

EMPEROR-Preserved investigator Stefan Anker discusses the role of SGLT2 inhibitors in patients with heart failure.